Aim: The intricate development of Parkinson's disease (PD) has posed a significant challenge in finding effective treatments. In the current study, a diaryl pyrrole compound, 1-(2-chlorophenyl)-2-methyl-5-(4-chlorophenyl)-1H-Pyrrole, was designed, synthesized, and tested for possible motor function improvement in 6-hydroxydopamine (6-OHDA) induced neurotoxicity in a rat model of PD.Method: Parkinsonism was triggered unilaterally by injecting 6-OHDA (12μg/4μl/rat) into the striatum. The compound (1,5,10 and 30 mg/kg) was then given intraperitoneally for 14 consecutive days following the 6-OHDA administration. To assess the compound's impact on motor function, the rats underwent behavioral tests, including beam walking, pole, open field, catalepsy and apomorphine-induced contralateral rotation tests on the 14th day. The possible inhibition activity of the pyrrole compound on COX-1/COX-2 was studied by molecular docking.Result: The motor impairments induced by 6-OHDA encompass akinesia (beam walking test), bradykinesia (beam walking, pole tests), motor coordination deficits (beam walking, pole tests), immobility (catalepsy test), locomotor activity (open field test) and rigidity (catalepsy test). Furthermore, animals injected with 6-OHDA exhibited contralateral rotation in response to apomorphine. Our findings demonstrated that the pyrrolic compound (30 mg/kg) ameliorated motor impairments. This compound has shown selective inhibition of COX-2 expression and a suppressive effect on PGE2 production in a previous study. Molecular docking study also suggested that the compound interacts with the key amino acids in COX-1/COX-2 active site, showing similar interaction energies in comparison with co-crystallized reference drugs.Conclusion: Present study manifested that post-lesion administration of 1-(2-chlorophenyl)-2-methyl-5-(4-chlorophenyl)-1H-Pyrrole could be considered a promising prospect for attenuating motor decline in PD.